Status:
COMPLETED
A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer
Lead Sponsor:
AstraZeneca
Conditions:
Gastrointestinal Hemorrhage
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.
Eligibility Criteria
Inclusion
- Signs of a bleeding in the stomach
- One endoscopically confirmed bleeding ulcer in the stomach or duodenum
Exclusion
- Malignancy or other advanced disease.
- Major cardiovascular event.
- Severe hepatic disease
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
1312 Patients enrolled
Trial Details
Trial ID
NCT00251979
Start Date
October 1 2005
End Date
December 1 2007
Last Update
June 17 2011
Active Locations (78)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Braunau/Inn, Austria
2
Research Site
Feldbach, Austria
3
Research Site
Graz, Austria
4
Research Site
Krems, Austria